JPRN-UMIN000005246已完成1 期
Phase I Clinical Study on the Combination Therapy of CHP-NY-ESO-1 Cancer Vaccine and MIS416 for the Treatment of Patients with NY-ESO-1 expressing Refractory Urothelial or Prostate Cancer - Phase I Clinical Study on the Combination Therapy of CHP-NY-ESO-1 Cancer Vaccine and MIS416 for the Treatment of Patients with NY-ESO-1 expressing Refractory Urothelial or Prostate Cancer
Mie University Graduate School of Medicine0 个研究点目标入组 12 人开始时间: 2011年3月14日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Past history of severe hypersensitivity. 2)Positive for HBs antigen, HCV antibody or HIV antibody. 3)Experience of autoimmune disease requiring treatment during 6 months preceding the day of consent. 4)Active multiple primaries. Simultaneous or metachronous with disease-free interval of 5 years or more. 5)Patient with disease requiring emergent radiotherapy. 6)Use of steroids (more than 20 mg equivalent of prednisolone/day) or immunosup-pressive drugs. 7)Patients with severe complication(s). 8)History of other NY-ESO-1-related immunotherapy. 9)Pregnant, lactating, or unprotected female. 10)Any other cases that the attending doctor judges not appropriate to enroll to this study.
研究者
相似试验
招募中
1 期
Phase 1 clinical study on the combination therapy of CHP-NY-ESO-1 cancer vaccine and Poly-ICLC for the treatment of patients with NY-ESO-1 expressing refractory esophageal cancerRefractory esophageal cancerJPRN-UMIN000007961Kyoto Prefectural University of Medicine18
已完成
1 期
Phase I/II study on combination therapy consisting of a fixed dose-rate infusion of gemcitabine with oral fluorinated pyrimidine compound S-1 (FGS) in patients with gemcitabine-refractory advanced pancreatic cancerPatients with gemcitabine-refractory metastatic pancreatic cancerJPRN-C000000450ational Cancer Center Hospital, Hepatobiliary and Pancreatic Oncology Division40
尚未招募
不适用
Phase I and II trial of combination therapy using nab-Paclitaxel+Pertuzumab+Trastuzumab for HER2 positive metastatic breast cancermetastatic breast cancerJPRN-UMIN000035869The University of Tokushima Graduate School, Depertment of Thoracic, Endocrine surgery and Oncology, Institute of Health Bioscience30
已完成
不适用
The phase I clinical study about the combined therapy, high purity natural killer (NK) cell therapy and IgG1 antibody to inoperable advance and recurrence digestive cancerJPRN-UMIN000013378Kyoto Prefectural University of Medicine9
已完成
不适用
A study to evaluate the safety and tolerability of doxorubicin and durvalumab, in patients with advanced soft tissue sarcoma.KCT0003577Yonsei University Health System, Severance Hospital45